Navigation Links
Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
Date:3/11/2008

s the gastric pH and thus protects omeprazole from acid degradation.

Important Safety Information about ZEGERID

The most frequently reported adverse events with ZEGERID are headache, diarrhea, and abdominal pain. Symptomatic response to therapy does not preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long term with omeprazole.

ZEGERID contains sodium bicarbonate. This should be taken into consideration for patients on a sodium-restricted diet.

ZEGERID is contraindicated in patients with known hypersensitivity to any component of the formulation.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the future regulatory approval and potential for ZEGERID. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
2. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
3. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
4. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
5. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
6. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
7. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
8. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
9. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
10. Schering-Plough Completes Acquisition of Organon BioSciences
11. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... The North American crystal oscillator market ... with analysis and forecast of revenue. This market was ... to reach $623.6 million by 2018, at a CAGR ... the TOC of the North American crystal oscillator market ... provided. This also provides a glimpse of the segmentation ...
(Date:10/22/2014)... San Diego, CA (PRWEB) October 22, 2014 ... laboratory balances from Sartorius, A & D Weighing, ... Sartorius CPA Semi-Micro Balance . The Sartorius ... looking for an affordable high-quality, precise, and user-friendly ... in manufacturing of laboratory equipment, their laboratory balances ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, announced today ... a Notice of Allowance for a composition of matter ... C. difficile program, SYN-004. This is Synthetic Biologics, ... the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
Breaking Biology Technology:The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... 11 VIA Pharmaceuticals,(Nasdaq: VIAP ), a ... the treatment of cardiovascular disease, announced today that,Lawrence ... Stewart, senior,vice president and chief financial officer, will ... Company 28th Annual Health Care Conference on,Tuesday, March ...
... FRANCISCO, Calif., March 11 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... the discovery, development and commercialization of,novel small-molecule therapeutics, ... year ended December 31, 2007., Total revenue ... million, with a,net loss of $8.8 million. Total ...
... March 11 Pharmacopeia,(Nasdaq: PCOP ), an innovator ... today announced that Dr. Leslie J. Browne,President and Chief ... and Company 28th Annual Health Care Conference.,The conference will ... Boston Marriott,Copley Place, Boston, Massachusetts., Dr. Browne,s presentation ...
Cached Biology Technology:Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 2Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 3Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 4Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 5Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 6Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 7Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 8Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 9Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 10Pharmacopeia to Present at the Cowen and Company 28th Annual Health Care Conference 2Pharmacopeia to Present at the Cowen and Company 28th Annual Health Care Conference 3
(Date:10/18/2014)... a sample of patients with undiagnosed, suspected genetic conditions, ... with a higher molecular diagnostic yield than traditional molecular ... JAMA . The study is being released to coincide ... , Exome sequencing, which sequences the protein­coding region of ... material present in a cell or organism), has been ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2
... N.H. New research from Plymouth State University and ... bleeding horseshoe crabs for biomedical purposes causes short-term changes ... crabs, population decline in parts of the east coast. ... the blue blood from almost half a million living ...
... (Feb. 19, 2014) -- There are more than a trillion ... our brains. Each of these neurons contains millions of proteins ... form the complex networks of the brain still remains as ... For the first time, a group of scientists has been ...
... its food plants and parasitoids, has been going on for ... (ACG), a protected area of approximately 1200 km2 in ... of moths and butterflies are estimated to live in ACG. ... also numbering thousands of species. However, most of those wasps ...
Cached Biology News:Biomedical bleeding affects horseshoe crab behavior 2Biomedical bleeding affects horseshoe crab behavior 3Watching how the brain works 2Almost 200 new species of parasitoid wasps named after local parataxonomists in Costa Rica 2
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Antibodies were affinity purified using epitopes specific to PPP1CC immobilized on solid support....
Biology Products: